Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of …

A Sepriano, A Kerschbaumer, JS Smolen… - Annals of the …, 2020 - ard.bmj.com
Objectives To perform a systematic literature review (SLR) concerning the safety of synthetic
(s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 …

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with …

K Kastrati, D Aletaha, GR Burmester, E Chwala… - RMD open, 2022 - rmdopen.bmj.com
Objectives Informing an international task force updating the consensus statement on
efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) …

[PDF][PDF] Use of third-line therapies in advanced sarcoidosis

EE Lower, M Sturdivant, L Grate… - Clin Exp …, 2020 - clinexprheumatol.org
Use of third-line therapies in advanced sarcoidosis Page 1 Clinical and Experimental
Rheumatology 2020 Clinical and Experimental Rheumatology 2020; 38: 834-840. Use of third-line …

Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature …

R Caporali, Y Allanore, R Alten, B Combe… - Expert review of …, 2021 - Taylor & Francis
Objectives There are few comparative data for tumor necrosis factor inhibitors in patients
with rheumatoid arthritis (RA). Methods Historical data for reference product/biosimilar …

Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey

L Schots, L Grine, R Soenen… - Journal of Dermatological …, 2022 - Taylor & Francis
Background Therapeutic drug monitoring (TDM) may lead to more rational use of biologics.
Still, TDM is largely underexplored in psoriasis. Little is known about the dosing behavior of …

Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review

JG Letarouilly, JH Salmon, RM Flipo - Expert Opinion on Drug …, 2021 - Taylor & Francis
Introduction: Biologic treatments are a milestone in the management of rheumatoid arthritis
(RA) patients with an inadequate response to conventional synthetic treatments. With the …

Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective …

M Kondo, H Yamada - Modern Rheumatology, 2019 - academic.oup.com
Objectives: To assess long-term outcomes for seven biological disease-modifying
antirheumatic drugs (bDMARD s) and one Janus kinase (JAK)-inhibitor in rheumatoid arthrit …

Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Naïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis

V Rosenberg, G Chodick, Z Xue, F Faccin, H Amital - Advances in Therapy, 2023 - Springer
Introduction Biologic disease-modifying anti-rheumatics drugs (bDMARDs) and targeted
synthetic DMARDs (tsDMARDs) are important treatments for rheumatoid arthritis (RA). As …

Biosimilars vs originators: Are they the same?

P Sarzi-Puttini, D Marotto, R Caporali, M Galeazzi… - Autoimmunity …, 2019 - Elsevier
Biological drugs have revolutionised the treatment of rheumatic diseases, and the recent
expiry of the patents for many biological agents has generated considerable interest among …

The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam

HB Bui, HT Lai, TL Nguyen, TD Vu, NL Bui… - Reumatología …, 2024 - Elsevier
Objectives To describe the status of using biological Disease Modifying Anti Rheumatic
Drugs (bDMARDs) to treat rheumatoid arthritis (RA) and related factors. In addition, the study …